PersonaAI Selected for Ministry of Science and ICT’s AX Voucher Program...Leading Innovation in Automated Cell Therapy Regulatory Compliance with AI Agents View original image

Hyperautomation company PersonaAI (CEO Seungjae Yoo) has been selected for the “AX One-Stop Voucher” program run by the Ministry of Science and ICT. Based on this, the company announced that it will formally launch the development of an automated cell therapy regulatory compliance platform utilizing AI agents.


This initiative will be carried out through a consortium with CHA Biotech, Naver Cloud, and Mediiplus. A total of 2.6 billion won in government support will accelerate AI transformation (AX) in the bio industry.


Within this project, PersonaAI is responsible for the core tasks of developing AI agents and building the SaaS platform. In particular, the company’s focus is on automating the entire process—drafting, verifying, and managing—of CMC (Chemistry, Manufacturing, and Controls) regulatory documents, which are essential throughout cell therapy product development and manufacturing, leveraging AI-based technologies.


To accomplish this, PersonaAI is designing a multi-agent structure that combines a CMC-specialized large language model (LLM), a knowledge-based agent, and agents for document generation and validation. The platform will integrate and structure decentralized research and production data, and support automation across all processes, from drafting regulatory documents to review and verification, thereby ensuring both quality and efficiency.


CHA Biotech will apply the platform in real-world development and manufacturing environments for cell therapy products and will be responsible for empirical validation. Naver Cloud will provide a stable cloud infrastructure, while Mediiplus will establish systems for data structuring and quality validation to enhance the reliability of AI training datasets.


If this SaaS platform is successfully commercialized, it is expected to set a new standard in the global bio market, in addition to the domestic industry.


An official from PersonaAI stated, “This project is among the first cases to structurally innovate regulatory compliance in the bio sector using AI agents.” The official added, “Particularly, automation of CMC documentation can shorten drug development and approval timelines and significantly strengthen global regulatory response capabilities.”


The official continued, “PersonaAI plans to lead AI transformation (AX) in the bio industry with its multi-agent-based AI SaaS platform and develop it into a standardized solution that can expand into the global market in the future.”



Meanwhile, the AX One-Stop Voucher program is a government-led initiative aimed at expediting AI transformation among domestic companies by providing integrated support for AI solutions, cloud, and data utilization, thus strengthening digital competitiveness across industries.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing